CAR-T

The FDA has sent shockwaves through the off-the-shelf CAR-T space after it slapped a clinical hold on all of the Allogene Therapeutics Inc (NASDAQ: ALLO) AlloCAR T trials in response to an abnormality that could theoretically cause cancer. Related: Allogene's BCMA-...

EXUMA Biotech is focused on developing a Chimeric Antigen Receptor (CAR)-T cell product for liquid and solid tumors. Chairman and CEO Dr. Greg Frost spoke with Benzinga about patient access to CAR-T therapies, the technology behind the company's two tumor platforms and the impact the...

The curtains have come down on one of the most-watched annual biotech conferences. The 59th annual meeting of the American Society of Hematology was held Dec. 9-12 in Atlanta.  This year's meeting was all about competition in the CART-T space. Immunotherapy — the fifth pillar of...